Open Access Open Access  Restricted Access Subscription or Fee Access

Atypical Psychiatric Presentations of Autoimmune Encephalitis: A Case Series and Proposed Clinical Approach to Diagnosis

Erin Stolte, Jessica Hesthammer, Ehsan Dorri

Abstract


Background: knowledge and detection of seronegative autoimmune encephalitis (AE) is growing rapidly, but typical psychiatric presentations risk misdiagnosis or delay in diagnosis with worse prognostic outcomes. Paraclinical markers are useful when positive, and integral to the current diagnostic framework yet have limited sensitivities leaving an unknown percentage of patients without diagnosis or treatment. Cases not meeting diagnostic criteria pose a particular clinical challenge regarding diagnosis and treatment decision making and highlight the need for further understanding of AE as well as the role of autoimmunity in psychiatric illness itself. Methods: Informed consent was obtained from five patients, three females and two males, in accordance with the University of Alberta medical ethics guidelines and regulations. Literature was reviewed for clinical features correlating with AE and compared to primary psychiatric illnesses of bipolar and schizophrenia. Results: Five cases of atypical, suspected AE not meeting diagnostic criteria are described with primarily psychiatric symptoms and minimal paraclinical features yet responded to immune therapy. Conclusions: Diagnostic challenges occur when patients present with features suspicious of autoimmune etiology yet do not meet criteria based on minimal paraclinical supportive findings. To what degree these false negatives exist more broadly is unknown yet raises further questions around consideration of immune treatment vs standard psychiatric care, especially if a subset can have a better prognostic outcome where they offered such treatments. Speculation occurs in the literature around whether these represent a false negative or undetected AE, a discrete entity such as autoimmune psychosis, or inflammatory mediated psychiatric illness.


Keywords


Autoimmune encephalitis , Paraclinical markers ,schizophrenia, Diagnostic challenges , autoimmune psychosis

Full Text:

PDF

References


Freund B, and Ritzl EK, A review of EEG in anti NMDA receptor encephalitis. Journal of neuroimmunology. 2019; 332, 64-68.

Gable MS, Sheriff H, Dalmau J, Tilley DH, Glaser CA , The frequency of autoimmune N-methyl-D-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California Encephalitis Project. Clin Infect Dis.2012; 54(7):899-904.

Liu CY, Zhu J, Zheng XY, et.al, Anti-N-Methyl-D-aspartate Receptor Encephalitis: A Severe, Potentially Reversible Autoimmune Encephalitis. Mediators Inflamm.2017

Najjar S, Steiner J, Najjar A, Bechter K, A clinical approach to new onset psychosis associated with immune dysregulation: the concept of autoimmune psychosis. J. Neuroinflammation,.2018; 15(1):1-8

Al-Diwani A, Handel A, Townsend L, et al, The psychopathology of NMDAR-antibody encephalitis in adults: a systematic review and phenotypic analysis of individual patient data. Lancet Psychiatry.2019; 6(3):235-246.

Graus, et. al, A clinical approach to diagnosis of autoimmune encephalitis. Lancet neurol.2016; 15(4):391-402

Mittal MK, Rabinstein AA, Hocker SE, et.al. Autoimmune encephalitis in the ICU: analysis of phenotypes, serologic findings, and outcomes. Neurocritical Care.2016; 24(2), 240-250.

Hacohen Y, Wright S, Waters P, et al. Paediatric autoimmune encephalopathies: clinical features, laboratory investigations and outcomes in patients with or without antibodies to known central nervous system autoantigens. J Neurol Neurosurg Psychiatry.2013;84(7):748-755.

Turpin, S, Martineau P, Lavasseur M et al. 18F-Flurodeoxyglucose positron emission tomography with computed tomography (FDG PET/CT) findings in children with encephalitis and comparison to conventional imaging. European Journal of nuclear medicine and molecular imaging.2019; 46:1309-1324

Probasco J, Solnes L, Nalluri A et al. Abnormal brain metabolism on FDG-PET/CT is a common early finding in autoimmune encephalitis. Neurol Neuroimmmunol Neuroinflamm.2017;4(4).

Nobrega et al. Clinical features and inflammatory markers in autoimmune encephalitis associated with antibodies against neuronal surface in brazilian patients. Front Neurol.2019; 10:472.

Espinola-Nadurillle et al. Non-inflammatory cerebrospinal fluid delays the diagnosis and start of immunotherapy in Anti-NMDAR encephalitis. Arq Neuropsiquiatr.2018;76(1):2-5

Pollak T et al. Autoimmune psychosis: an international consensus on an approach to the diagnosis and management of psychosis of suspected autoimmune origin. Lancet Psychiatry. 2020; 7(1):93-108.

Giordano A et al. Diagnosing autoimmune encephalitis in a real‑world single‑centre setting. Journal of Neurology.2020; 267: 449–460

Hebert J et al. Searching for autoimmune encephalitis: Beware of normal CSF. Journal of Neuroimmunology.2020;345:577285

Endres D et al. Autoantibody-associated psychiatric syndromes: a systematic literature review resulting in 145 cases. Psychological Medicine.2022;52(6):1135-46

Warren N et al. Serum and CSF Anti-NMDAR Antibody Testing in Psychiatry (2020). J Neuropsychiatry Clin Neurosci. 2020; 32(2):154–160.

Moreno-Ajona D et al, Article 18F-FDG-PET Imaging Patterns in Autoimmune Encephalitis: Impact of Image Analysis on the Results. Diagnostics.2020; 10(6): 356

Weng W et al, Different FDG-PET metabolic patterns of anti-AMPAR and anti-NMDAR encephalitis: Case report and literature review. Brain and Behavior. 2020; 10(3): e01540.

Yuan J, Guan H, Zhou X et al , Changing Brain Metabolism Patterns in Patients with ANMDARE; Serial F-DG PET/CT findings. Clinical Nuclear Medicine. 2016;41(5):366-70

Endres D et al, Autoimmune encephalitis as a differential diagnosis of schizophreniform psychosis: clinical symptomatology, pathophysiology, diagnostic approach, and therapeutic considerations. European Archives of Psychiatry and Clinical Neuroscience.2020; 270:803–818.

Scholl et al. Fluorodeoxyglucose PET in Neurology and Psychiatry. PET Clinics.2014; 9(4):371-390.

Shinto et al. Hyperfrontality as seen on FDG PET in unmedicated schizophrenia patients with positive symptoms. Clin Nucl Med.2014;39(8):694-7

Seethalaskshmi et al, Regional brain metabolism in schizophrenia: An FDG-PET study. Indian J Psychiatry.2006; 48(3):149-53

Lee et al. 18F-Fluorodeoxyglucose Positron-Emission Tomography Findings with Anti-N-Methyl-D-Aspartate Receptor Encephalitis that Showed Variable Degress of Catatonia: Three Cases report. J Epilepsy Res.2014; 4(2):69-73

Hansen N and Timäus C, et al, Autoimmune encephalitis with psychiatric features in adults: historical evolution and prospective challenge. Journal of Neural Transmission.2021;128:357-69

Mané-Damas M, Hoffmann C, Zong S, et al, Autoimmunity in psychotic disorders. Where we stand, challenges and opportunities. Autoimmun Rev.2019; 18(9):102348.

Herken J and Pruss H. Red Flags: Clinical signs for identifying autoimmune encephalitis in psychiatric patients. Front. Psychiatry.2017; 8:25.

Ganesh A et al. Worldwide survey of neurologists on approach to autoimmune encephalitis. Neurology: Clinical Practice.2020;10(2), 140-148.

Ferrafiat, V et al. A causality algorithm to guide diagnosis and treatment of catatonia due to autoimmune conditions in children and adolescents. Schizophrenia Res.2018;200:68-76

Warrington T, Bostwick J. Psychiatric adverse effects of corticosteroids. Mayo Clin Proc.2006; 81(10):1361-7.

Janes M, Kuster S, Goldson TM, Forjuoh SN (2019). Steroid-induced psychosis. Proc (Bayl Univ Med Cent).2019; 32(4):614-615.

Rossignol DA, Frye RE. A Systematic Review and Meta-Analysis of Immunoglobulin G Abnormalities and the Therapeutic Use of Intravenous Immunoglobulins (IVIG) in Autism Spectrum Disorder. J Pers Med. 2021;11(6):488.

Dodel R, Rominger A, Bartenstein P, et al . Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol.2013; 12(3):233-243.

Titulaer MJ et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol.2013; 12(2):157-65.

Kelley BP, Patel SC, Marin HL, et al. Autoimmune Encephalitis: Pathophysiology and Imaging Review of an Overlooked Diagnosis. AJNR Am J Neuroradiol.2017;22(1): 1-3

Balu R, McCracken L, Lancaster E, et al. A score that predicts 1-year functional status in patients with anti-NMDA receptor encephalitis. Neurology.2019; 92(3):e244-e252.

Friedrich ME et al. Cardiovascular Adverse Reactions During Antipsychotic Treatment: Results of AMSP, A Drug Surveillance Program Between 1993 and 2013. Int J Neuropsychopharmacol.2020; 23(2):67-75.

Jin H, Tappenden P, Robinson S, et al. Systematic review of the methods of health economic models assessing antipsychotic medication for schizophrenia. PLoS One.2020; 15(7):e0234996

Bechter, C. Schizophrenia—a mild encephalitis? Fortschr Neurol Psychiatr. 2013;81(5):250-9.

Ponte A et al. Catatonia in Anti-N-Methyl-D-Aspartate (NMDA) Receptor Encephalitis Misdiagnosed as Schizophrenia. Acta Med Port.2020; 33(3):208-211.

Lodge D, Mercier MS. Ketamine and phencyclidine: the good, the bad and the unexpected. Br J Pharmacol.2015;172(17):4254-4276.

Nguyen A et al. Psychiatric Prodrome in Anti-NMDAR Associated Encephalopathy: Clinical and Pathophysiologic Considerations. Prim Care Companion CNS Disorders.2020; 22(3):27162

Ellul P, Groc L, Tamouza R, Leboyer M. The Clinical Challenge of Autoimmune Psychosis: Learning from Anti-NMDA Receptor Autoantibodies. Front Psychiatry.2017; 8:54.

Endres D et al. Autoimmune encephalitis as a differential diagnosis of schizophreniform psychosis: clinical symptomatology, pathophysiology, diagnostic approach, and therapeutic considerations. European Archives of Psychiatry and Clinical Neuroscience.2020; 270(7): 803-818.

Al-Diwani AA, Pollak TA, Irani S, et al. Psychosis: an autoimmune disease? Immunology.2017; 152(3): 388-401

Endres D et al. Cerebrospinal fluid, antineuronal autoantibody, EEG, and MRI findings from 992 patients with schizophreniform and affective psychosis. Translational Psychiatry.2020; 10(1):1-20.

Benrós ME and Mortensen PB. The Role of Infections and Autoimmune Diseases for Schizophrenia and Depression: Findings from Large-Scale Epidemiological Studies. Immunology and Psychiatry.2015:pp107-135

Sommer I et al. Severe chronic psychosis after allogeneic SCT from a schizophrenic sibling. Bone Marrow Transplant.2015; 50(1):153–154,

Miyaoka T. Remission of Psychosis in Treatment-Resistant Schizophrenia following Bone Marrow Transplantation: A Case Report. Front Psychiatry. 2017; 8: 174.

Steiner J et al. Innate Immune Cells and C-Reactive Protein in Acute First-Episode Psychosis and Schizophrenia: Relationship to Psychopathology and Treatment. Schizophr Bull. 2020; 46(2): 363-373.

Timucin et al. The role of NMDAR antibody in the etiopathogenesis of schizophrenia. Neuropsychiatr Dis Treat.2016; 12:2327-2332

Jezequel J et al. Dynamic disorganization of synaptic NMDA receptors triggered by autoantibodies from psychotic patients. Nature Communications.2017; 18(1):1-5

Jones JD, Hamilton BJ, Rigby WF. Rituximab mediates loss of CD19 on B cells in the absence of cell death. Arthritis Rheum.2012; 64(10):3111-3118.

Van Laar JM. B-cell depletion with rituximab: a promising treatment for diffuse cutaneous systemic sclerosis. Arthritis Res Ther. 2010; 12(2):1-2.

Shin YW et al. Treatment strategies for autoimmune encephalitis. Ther Adv Neurol Disord. 2108; 11: 1756285617722347.

Lee WJ et al. Tocilizumab in Autoimmune encephalitis refractory to rituximab: an institutional cohort study. Neurotherapeutics.2016; 13(4):824-832.

Mihara M, Ohsugi Y, Kishimoto T. Tocilizumab, a humanized anti-interleukin-6 receptor antibody, for treatment of rheumatoid arthritis. Open Access Rheumatol.2011; 3:19-29.

Muller N. Immunology of schizophreni. Neuroimmunomodulation, 2014; 21(2-3):109-16.

Muller N. Inflammation in schizophrenia: pathogenetic aspects and therapeutic considerations. Schizophr Bull.2018; 44(5):973-982.

Boiko AS. Cytokine Level Changes in Schizophrenia Patients with and without Metabolic Syndrome Treated with Atypical Antipsychotics. Pharmaceuticals (Basel).2021; 14(5)

Titulaer MJ, McCracken L, Gabilondo I, et al (2013). Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol., 12(2):157-65.

Kayser MS, Titulaer MJ, Gresa-Arribas N, Dalmau J (2013). Frequency and characteristics of isolated psychiatric episodes in anti–N-methyl-d-aspartate receptor encephalitis. JAMA Neurol., 70(9):1133-9.

Soares HR, Cavalcante WCP, Martins SN, Smid J, Nitrini R (2016). Capgras syndrome associated with limbic encephalitis in a patient with diffuse large B-cell lymphoma. Dement Neuropsychol., 10(1):63-69.

Salvatore P, Bhuvaneswar C, Tohen M, Khalsa HM, Maggini C, Baldessarini RJ (2014).Capgras' syndrome in first-episode psychotic disorders. Psychopathology. 47(4):261-9.

Smith et al (2011). N-methyl-D-aspartate Receptor Autoimmune Encephalitis Presenting With Opsoclonus-MyoclonusTreatment Response to Plasmapheresis. Arch Neurol.,2668(8):1069-1072.

Maeder-Ingvar M, Prior JO, Irani SR, et al (2011). FDG-PET hyperactivity in basal ganglia correlating with clinical course in anti–NDMA-R antibodies encephalitis. Journal of Neurology, Neurosurgery & Psychiatry, 82:235-236.

Leypoldt F, Armangue T, Dalmau J (2014). Autoimmune encephalopathies. Ann N Y Acad Sci., 1338(1):94-114.

Fusar-Poli P, Cappucciati M, De Micheli A, et al (2016). Diagnostic and Prognostic Significance of Brief Limited Intermittent Psychotic Symptoms (BLIPS) in Individuals at Ultra High Risk. Schizophr Bull., 43(1):48-56.

Herken J, Prüss H (2017). Red Flags: Clinical Signs for Identifying Autoimmune Encephalitis in Psychiatric Patients. Front Psychiatry, 8:25,doi:10.3389/fpsyt.2017.00025.

Ferrafiat, et al (2017). A causality algorithm to guide diagnosis and treatment of catatonia due to autoimmune conditions in children and adolescents. Schiz Research, 200:6876,doi:10.1016/j.schres.2017.06.036.

Piepgras J, Höltje M, Michel K, et al (2015). Anti-DPPX encephalitis: pathogenic effects of antibodies on gut and brain neurons. Neurology, 85(10):890-7.

Gejman PV, Sanders AR, Kendler KS (2011). Genetics of schizophrenia: new findings and challenges. Annu Rev Genomics Hum Genet., 12:121–44


Refbacks

  • There are currently no refbacks.


Copyright (c) 2022 Research & Reviews: Journal of Neuroscience